deltatrials
Terminated PHASE1 INTERVENTIONAL 3-arm NCT05107856

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection as Monotherapy or in Combination With Azacitidine or Venetoclax in Patients With Relapsed/Refractory Myeloid or B-cell Malignancies

Sponsor: Prelude Therapeutics

Conditions Acute Myeloid Leukemia B-cell Non-Hodgkin Lymphoma Chronic Lymphocytic Leukemia Chronic Myelomonocytic Leukemia Follicular Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Myelodysplastic Syndromes Myeloproliferative Neoplasm Small Lymphocytic Lymphoma
Interventions Azacitidine PRT1419 Venetoclax
Updated 14 times since 2021 Last updated: Jan 29, 2024 Started: Mar 22, 2022 Primary completion: Jan 19, 2024 Completion: Jan 19, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Company Decision

Other terminated trials from Prelude Therapeutics

See all terminations from Prelude Therapeutics

Other Acute Myeloid Leukemia trials with similar outcome

Browse all Acute Myeloid Leukemia trials

Listed as NCT05107856, this PHASE1 trial focuses on Acute Myeloid Leukemia and B-cell Non-Hodgkin Lymphoma and remains terminated or withdrawn. Sponsored by Prelude Therapeutics, it has been updated 14 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Mar 2023 · 3 months · monthly snapshot~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Dec 2023 · 7 months · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Feb 2024 — Jul 2024 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  4. Jan 2024 — Feb 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Dec 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

▶ Show 9 earlier versions

  1. May 2023 — Dec 2023 [monthly]

    Recruiting PHASE1

  2. Mar 2023 — May 2023 [monthly]

    Recruiting PHASE1

  3. Dec 2022 — Mar 2023 [monthly]

    Recruiting PHASE1

  4. Sep 2022 — Dec 2022 [monthly]

    Recruiting PHASE1

  5. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  6. May 2022 — Jul 2022 [monthly]

    Recruiting PHASE1

  7. Feb 2022 — May 2022 [monthly]

    Recruiting PHASE1

  8. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  9. Dec 2021 — Jan 2022 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Prelude Therapeutics
Data source: Prelude Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations